Synthesis and characterization of miniaturized aptamer-based monolithic sorbent for selective extraction of β-amyloid peptides from cerebrospinal fluid.

Israel Donizeti de Souza, Caroline Fernandes Grecco, Maria Eugênia Costa Queiroz, Valerie Pichon, Audrey Combès

Abstract read

In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Israel Donizeti de SouzaDepartment of Analytical, Bioanalytical Sciences and Miniaturization (LSABM), Chemistry, Biology and Innovation (CBI), UMR 8231 ESPCI Paris - CNRS, ESPCI Paris, PSL University, 10 Rue Vauquelin, 75005, Paris, France.

Caroline Fernandes GreccoDepartment of Analytical, Bioanalytical Sciences and Miniaturization (LSABM), Chemistry, Biology and Innovation (CBI), UMR 8231 ESPCI Paris - CNRS, ESPCI Paris, PSL University, 10 Rue Vauquelin, 75005, Paris, France.

Maria Eugênia Costa QueirozDepartamento de Química da Faculdade de Filosofia, Ciências E Letras de Ribeirão Preto (DQ-FFCLRP), Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.

Valerie PichonDepartment of Analytical, Bioanalytical Sciences and Miniaturization (LSABM), Chemistry, Biology and Innovation (CBI), UMR 8231 ESPCI Paris - CNRS, ESPCI Paris, PSL University, 10 Rue Vauquelin, 75005, Paris, France.

Audrey CombèsDepartment of Analytical, Bioanalytical Sciences and Miniaturization (LSABM), Chemistry, Biology and Innovation (CBI), UMR 8231 ESPCI Paris - CNRS, ESPCI Paris, PSL University, 10 Rue Vauquelin, 75005, Paris, France. audrey.combes@espci.fr.ORCID http://orcid.org/0000-0003-3318-7230

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ratio between beta-amyloid (Aβ) peptides 40 and 42 is recognized as a biomarker for Alzheimer's disease, playing a significant role in early diagnosis and disease progression monitoring. Aβ peptides are present at trace levels in cerebrospinal fluid, therefore, developing a new selective extraction procedure is essential for isolating targeted biomarkers from the matrix interferents, ensuring accurate identification and quantification. In this study, a hybrid organic-silica monolith was synthesized in a 530 µm inner diameter-capillary and used for the covalent grafting of beta amyloid peptide aptamers. The resulting miniaturized oligosorbent (mOS) was applied to selectively extract Aβ peptides 40 and 42 from artificial cerebrospinal fluid (CSF) samples. The immobilization procedure achieved grafting yields higher than 90% leading to a dense coverage of Aβ aptamers (655 + 15 pmol.µL

Indexed as

Amyloid beta-PeptidesAptamers, NucleotideAptamers, PeptidePeptide FragmentsSolid Phase ExtractionAdsorptionAlzheimer DiseaseHumansLimit of DetectionSilicon DioxideAmyloid beta-PeptidesAptamers, NucleotideAptamers, PeptidePeptide FragmentsSilicon DioxideAmyloid beta peptideAptamersBiomarkersCerebrospinal fluidMiniaturized oligosorbentsMonolith

Identifiers

PMID40887520

DOI10.1007/s00216-025-06085-7

PMCPMC12532768

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.